Gilead Collaborates with Merck to Jointly Develop and Commercialize Lenacapavir + Islatravir for HIV

 Gilead Collaborates with Merck to Jointly Develop and Commercialize Lenacapavir + Islatravir for HIV

Gilead Collaborates with Merck to Jointly Develop and Commercialize Lenacapavir + Islatravir for HIV

Shots:

  • The companies will co-develop & co-commercialize the combination of Gilead’s Lenacapavir and Merck’s Islatravir in long-acting oral & injectable formulations for HIV. Gilead & Merck will share global development & commercialization costs (60%/40%) respectively
  • For oral products, Gilead will lead commercialization in the US & Merck will lead in the EU & ROW while for injectables, commercialization will be vice versa. Additionally, each company will exercise its option to acquire the license for an investigational oral integrase inhibitor of the other company, following completion of the first P-I trial
  • Upon exercise of an option, the companies will split development cost & revenues, unless the non-exercising company decides to opt-out. Both companies’ integrase inhibitors are currently in preclinical development

Click here ­to­ read full press release/ article | Ref: Businesswire | Image: Report Door

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post